Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues-Reference-Cited by-同舟云学术

Durable cell and gene therapy potential patient and financial impact: US projections of product approvals, patients treated, and product revenues

Published:2022-01 Issue:1 Volume:27 Page:17-30
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Young Colin M.,Quinn Casey,Trusheim Mark R.

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference34 articles.

1. Use of viruses as carriers of added genetic information;Rogers;Nature,1968

2. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity;Gross;Proc Natl Acad Sci USA,1989

3. Tracking the CAR-T Revolution: Analysis of Clinical Trials of CAR-T and TCR-T Therapies for the Treatment of Cancer (1997–2020);Ivica;Healthcare,2021

4. Schmickel B, Perry K, Sanchez H, Francis F, Haber A, Davis C et al. Exploring the Truth of Reimbursement Challenges for Cell and Gene Therapies. https://trinitylifesciences.com/wp-content/uploads/2019/06/Trinity_Reimbursement_Challenges-6.10.19-1.pdf [Accessed September 8, 2021].

5. Gardner J. How Many Million-Dollar Drugs Can Health Systems Tolerate? www.evaluate.com/vantage/articles/analysis/spotlight/how-many-million-dollar-drugs-can-health-systems-tolerate [Accessed September 8, 2021].

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Estimated Spending on Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa;JAMA Dermatology;2024-01-31

2. Emerging Therapeutics and Delivery;Pharmaceutics;2024

3. Using Real-World Data to Inform Value-Based Contracts for Cell and Gene Therapies in Medicaid;PharmacoEconomics;2023-11-21

4. 2017-2023: state of the art of gene therapies in rare diseases in Europe: the dynamics of clinical R&D, new approved treatments and expected therapies in the pipelines;Rare Disease and Orphan Drugs Journal;2023-11-03

5. Confronting High Costs And Clinical Uncertainty: Innovative Payment Models For Gene Therapies;HEALTH AFFAIR;2023